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Scientific objectives
Urolithiasis is a widespread disease in the developed
countries with rising prevalence rates which presently lie
at least at 5%. Thus, 25 Mio. EU-citizens suffer from
that symptom which burdens the healthcare systems by
several tens of billions of Euros yearly. Stone formation
is the result of an altered urinary composition, mostly
caused by an underlying metabolic disease and disad-
vantageously interacting external risk factors. This
makes the pathogenesis in each patient unique and thus
diagnosis, causal treatment and therapeutic monitoring
difficult, costly and time-consuming. Mostly, no specific
long-term therapy for prevention of recurrence follows
the purely symptom-based stone removal.
The consequence is a diagnostic and therapeutic
under-supply which inevitably results in a vicious circle
of recurrent stone formation, although the recurrence
rate can be lowered from 80% without metaphylaxis
down to 20% under risk-adopted therapy. A paradigm
shift from “stone-removal-only” towards a predictive,
preventive and personalized treatment according to
guideline recommendations is required. Routine urinaly-
sis is restricted to only a few selected lithogenically
important constituents whose concentrations partly can
be combined to indices. However, to date no simple,
cost-effective and precise method to determine the crys-
tal formation risk of a native urine exists on the market.
Technological approaches
The scientifically established Bonn-Risk-Index (BRI) is
based on a crystallization test induced within a sample
of native urine. As urine composition reflects the
influence of any of the patient’s metabolic processes –
even of those analytically not directly accessible – BRI
reflects a patient’s risk situation on a highly personalized
level. BRI has proven its excellent appropriateness by
showing diagnostic sensitivity and specificity clearly
exceeding even those of the most evolved analysis-based
risk indices. Whereas BRI can be cheaply and benefi-
cially determined within a few minutes, standard urina-
lysis needs unacceptable amounts of time and costs. In
2008 the “Urolizer” mini-lab for fully-automated BRI
measurement was developed; some devices are still in
use. Experience shows that the requirements of medical
laboratories, hospitals and medical offices differ in part.
Whereas the former are very satisfied about the Uroli-
zer, the latter two asked again for a simplified BRI test
device.
Results interpretation
In preliminary tests the basic feasibility of an alternative
approach of BRI-determination was demonstrated. Cur-
rently, a miniaturized point-of-care test device is being
developed. The disposable “BRI-on-Chip” meets particu-
larly the requirements of the resident doctors. The
result is presented in three levels within a few seconds.
Outlook
The BRI-on-Chip approach perfectly fits both the medi-
cal and socio-economical needs as: (1) an inexpensive,
reliable, intuitively and easy-to-use diagnostic tool for
the evaluation of the urinary stone formation risk is
given to the physicians allowing them to better apply an
appropriate stone metaphylaxis, and (2) it helps to
reduce the continuously increasing urolithiasis-related
costs as the recurrence rates will be consecutively* Correspondence: norbert.laube@nttf-coatings.de
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lowered. It can be expected, that the BRI-principle
allows also for the screening of other metabolic diseases.
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Figure 1 The BRI facilitates to leave the vicious circle.
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